Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2021

View Archived Issues

AFYX Therapeutics presents preclinical data on anti-TNF antibody delivery through adhesive patch

Small-molecule OXS-7417 shows in vivo AML antitumoral effects

StemSynergy Therapeutics patents N-myc proto-oncogene protein inhibitors

Salk Institute, Sanford Burnham Prebys describe new ULK1 inhibitors

New PIKfyve inhibitors identified at AcuraStem

Discovery of novel antibiotic class of tethered macrocyclic peptides

Novel virulence factor LasB inhibitors for the treatment of P. aeruginosa infections

HA-344 shows promise for treating cutaneous metastatic melanoma

PearlRiverBio patents mutant EGFR/HER2 inhibitors

STM-2457: a first-in-class METTL3 inhibitor with preclinical proof of concept in AML models

Flamingo and Ionis expand alliance to develop RNA-targeted therapies for oncology

GRC-39815 shows efficacy in models of smoke-induced COPD

Vitalgenics reports preclinical findings with excindogen in PDAC

Twist collaborates with Boehringer Ingelheim on antibody research programs

KG207-M, a novel bifunctional fusion protein as disease-modifying therapy for AD

Platinum(II)-NHC complex targeting vimentin inhibits tumor metastasis

fMLP receptor promotes inflammatory brain injury

At WCLC, early steps towards success against SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...